Eric J Velazquez
Overview
Explore the profile of Eric J Velazquez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
341
Citations
12130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryan M, Petrie M, Kontopantelis E, Dodd M, Tong G, Marquis-Gravel G, et al.
Eur Heart J
. 2025 Mar;
PMID: 40048661
Background And Aims: In the Surgical Treatment for Ischaemic Heart Failure Trial Extension Study (STICHES), coronary artery bypass grafting (CABG) improved outcomes of patients with ischaemic left ventricular dysfunction receiving...
2.
Kokkinidis D, Kyriakoulis I, Chui P, Agarwal R, Liu Y, Khera R, et al.
JACC Adv
. 2025 Feb;
4(3):101618.
PMID: 39983619
Background: Estimation of coronary artery calcification (CAC) can provide important prognostic information in patients with suspected coronary artery disease. Objectives: The authors aimed to investigate whether CAC evaluation offers additional...
3.
Nouhravesh N, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e037899.
PMID: 39968788
Background: Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in-hospital. Thus, this prespecified PARAGLIDE-HF (Prospective Comparison of ARNI With...
4.
Nouhravesh N, Gunn A, Cyr D, Hernandez A, Morrow D, Velazquez E, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792134
Aims: Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction...
5.
Shoji S, Cyr D, Hernandez A, Velazquez E, Ward J, Williamson K, et al.
Am Heart J
. 2024 Nov;
280:70-78.
PMID: 39505123
Background: The win ratio (WR) is an emerging alternative for reporting composite outcomes, prioritizing clinically significant events such as mortality while incorporating surrogate measures. However, its benefits should be weighed...
6.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, et al.
J Am Soc Nephrol
. 2024 Aug;
36(1):99-107.
PMID: 39196651
No abstract available.
7.
Ahmad Y, Petrie M, Jolicoeur E, Madhavan M, Velazquez E, Moses J, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
1(2):100020.
PMID: 39132568
Coronary artery disease (CAD) is the most common cause of left ventricular systolic dysfunction (LVSD) and heart failure (HF). Revascularization with coronary artery bypass grafting (CABG) reduces all-cause mortality compared...
8.
Lee Chuy K, Velazquez E, Lansky A, Jamil Y, Ahmad Y
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
2(6Part B):101197.
PMID: 39131064
Ischemic heart disease is the largest cause of death worldwide and the most common cause of heart failure (HF). The incidence and prevalence of HF are increasing owing to an...
9.
Fudim M, Cyr D, Ward J, Hernandez A, Lepage S, Morrow D, et al.
J Card Fail
. 2024 May;
30(12):1568-1577.
PMID: 38802053
Background: In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with...
10.
Oikonomou E, Aminorroaya A, Dhingra L, Partridge C, Velazquez E, Desai N, et al.
Eur Heart J Digit Health
. 2024 May;
5(3):303-313.
PMID: 38774380
Aims: An algorithmic strategy for anatomical vs. functional testing in suspected coronary artery disease (CAD) (Anatomical vs. Stress teSting decIsion Support Tool; ASSIST) is associated with better outcomes than random...